KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to -$21.1 billion.

  • Gsk's Accounts Payables fell 1321.85% to -$21.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.1 billion, marking a year-over-year decrease of 1321.85%. This contributed to the annual value of -$19.6 billion for FY2024, which is 19946.83% down from last year.
  • According to the latest figures from Q3 2025, Gsk's Accounts Payables is -$21.1 billion, which was down 1321.85% from -$19.8 billion recorded in Q2 2025.
  • Gsk's Accounts Payables' 5-year high stood at $23.7 billion during Q4 2021, with a 5-year trough of -$21.1 billion in Q3 2025.
  • For the 5-year period, Gsk's Accounts Payables averaged around -$12.1 billion, with its median value being -$18.7 billion (2024).
  • In the last 5 years, Gsk's Accounts Payables surged by 7907.26% in 2022 and then tumbled by 31135.42% in 2023.
  • Gsk's Accounts Payables (Quarter) stood at $23.7 billion in 2021, then decreased by 19.39% to $19.1 billion in 2022, then increased by 3.09% to $19.7 billion in 2023, then tumbled by 200.09% to -$19.7 billion in 2024, then fell by 7.44% to -$21.1 billion in 2025.
  • Its Accounts Payables was -$21.1 billion in Q3 2025, compared to -$19.8 billion in Q2 2025 and -$19.1 billion in Q1 2025.